Leaps by Bayer

R&D

Interview at BIO 2025 with Juergen Eckhardt

Looking to early-stage companies for innovation, with Juerge...

In an interview at BIO 2025, Bayer's Juergen Eckhardt discusses the importance of external innovation and why his company is prioritising early stage.

News

Lilly inflates US facility investment spending by $4.5bn

Having already committed last year to capital investments of $27 billion in the US to ward off the threat of tariffs, Eli Lilly has upped the ante.

/themes/custom/pharmaphorum_theme/library/img/article-label-image/register.png

Digital

Discover a new era of healthcare panel engagement: Grounded ...

A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.

Editor's Picks